Sasanlimab Plus BCG in BCG-Naive, High-Risk Non-Muscle Invasive Bladder Cancer: the Randomized Phase 3 CREST Trial

Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial

Bacillus Calmette–Guérin (BCG) induction and maintenance (I+M) after transurethral resection of bladder tumor is standard of care (SOC) in high-risk non-muscle invasive bladder cancer (NMIBC). However, disease recurrence/progression occurs in approximately 40% of patients at 2 years, with unfavorable prognosis. Limited bladder-sparing therapeutic options exist, and no improvements to response durability have been observed in decades. CREST is a …

Non-Surgical Option Approved for Recurrent Low-Grade Bladder Cancer

(MedPage Today) -- The FDA approved mitomycin intravesical solution (Zusduri) as a nonsurgical option for recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC). The product won the indication despite a negative recommendation...

Sasanlimab Combo Improves EFS “Across the Board” in BCG-Naïve NMIBC

Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.

Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

The FDA approved mitomycin intravesical solution (Zusduri) for patients with recurrent low-grade intermediate risk non–muscle-invasive bladder cancer (NMIBC).

FDA Approves UGN-102 For Some With Bladder Cancer

The FDA has granted approval to UGN-102 for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.

FDA Approves Mitomycin Intravesical Solution in Low-Grade NMIBC

UGN-102 has received FDA approval for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.